keyword
MENU ▼
Read by QxMD icon Read
search

Millennium oncology

keyword
https://www.readbyqxmd.com/read/29628465/-pharmacological-characteristics-and-clinical-study-results-of-the-oral-proteasome-inhibitor-ixazomib-ninlaro-%C3%A2-capsules-2-3-mg-3-mg-and-4-mg
#1
Michiko Machida, Shinichi Fukunaga, Takahito Hara
Ixazomib (Ninlaro® capsule) is an oral small molecule 20S proteasome inhibitor created by Millennium Pharmaceuticals, Inc (Takeda Oncology Company). Ubiquitin proteasome system is a major regulatory system for maintaining protein homeostasis, and an important mechanism for degrading proteins, such as those involved in proliferation regulation, cell cycle regulation and apoptosis, in cells. Ixazomib selectively and reversibly binds to the β5 subunit of the 20S proteasome, inhibits its chymotrypsin-like activity, and thereby accumulates ubiquitinated proteins...
2018: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/29504421/-milestones-in-liver-surgery
#2
Ferenc Jakab
Numerous outstanding summarizing publications on the milestones of the rapid development of liver surgery in the twentieth century came to light around the year 2000, therefore in this summary only the newest principles and novelties of liver surgery after the second millennium are presented. Among the new principles, the newest indications, the bloodless surgery and the vascular exclusion of the liver, the "associating liver partition and portal vein occlusion for staged hepatectomy" (ALPPS) - as presently the fastest and most successful method for liver regeneration, and the "downsizing of tumors" treatment for the interest of resection of unresectable tumours are analyzed and evaluated...
March 2018: Orvosi Hetilap
https://www.readbyqxmd.com/read/29504418/-changes-in-the-clinicopathological-features-of-surgically-treated-lung-cancer-around-the-millennium
#3
Tibor Géczi, Edit Csada, László Tiszlavicz, György Lázár, József Furák
INTRODUCTION: Lung cancer is the most common malignant tumor in Europe and Hungary. In 2010, 10 557 new cases were registered in Hungary; 80-85% of these cases were associated with smoking. AIM: In our work we analyzed the data of lung cancer patients of the last 15 years retrospectively. METHOD: We examined the demographic characteristics, the histological type, the stage of the lung cancer, the type of the surgical procedure used, other supplemental treatment and survival retrospectively...
March 2018: Orvosi Hetilap
https://www.readbyqxmd.com/read/29487982/-metastatic-breast-cancer-in-the-spine-molecular-predictors-for-choosing-adequate-treatment-strategies
#4
D Adler, M Kriegsmann, P Sinn, A Schneeweiss, H Almansour, B Lehner, M Akbar
Breast cancer is the most common malignancy affecting women and the spinal column is most likely affected by metastases. Modern oncologic treatment options have significantly prolonged survival times in the last decade. Therefore, treatment of vertebral metastases has been of special interest in spine surgery. Different scores are described to evaluate prognosis and to choose correct treatment strategies, which however only differentiate tumor entities and not specific tumor phenotypes. Breast cancer has been classified into five intrinsic subtypes with different survival rates since the turn of the millennium...
February 27, 2018: Der Orthopäde
https://www.readbyqxmd.com/read/28931101/-the-early-recognition-of-mental-morbidities-during-psycho-oncologic-treatment
#5
Mónika Mailáth, Réka Laczkóné Majer, Zsolt Horváth, Sándor Gergely Szabó
Unfortunately there have been no positive changes in the main indicators of cancer incidence in Hungarian population since the turn of the millennium. The main goal of psycho-oncologic treatment is to provide the highest possible quality of life to the patient. The prevalence of mental disorders in cancer patients is high and it is accompanied by a rather small number of qualified staff. Thus, the remedy might be the identification of high-risk patients, i.e. the systematic psycho-oncologic screening. Hungary is still lacking a unified screening method that involves all oncologic treatment-providing units...
September 20, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28832953/colchicine-an-ancient-drug-with-novel-applications
#6
REVIEW
B Dasgeb, D Kornreich, K McGuinn, L Okon, I Brownell, D L Sackett
Colchicine is a treatment for gout that has been used for more than a millennium. It is the treatment of choice for familial Mediterranean fever and its associated complication, amyloidosis. The 2009 U.S. Food and Drug Administration approval of colchicine as a new drug had research consequences. Recent investigations with large cohorts of patients with gout who have been taking colchicine for years have demonstrated novel applications within oncology, immunology, cardiology and dermatology. Some emerging dermatological uses include the treatment of epidermolysis bullosa acquisita, leucocytoclastic vasculitis, aphthous stomatitis and others...
February 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/28317239/the-use-of-low-dose-metronomic-chemotherapy-in-dogs-insight-into-a-modern-cancer-field
#7
REVIEW
T B Gaspar, J Henriques, L Marconato, F L Queiroga
The era of chemotherapy, which started in the middle of the last century, has been ruled by the routine use of dose-intense protocols, based on the "maximum-tolerated dose" concept. By promoting a balance between patient's quality of life and the goal of rapidly killing as many tumour cells as possible, these protocols still play a prominent role in veterinary oncology. However, with the opening of a new millennium, metronomic chemotherapy (MC) started to be considered a possible alternative to traditional dose-intense chemotherapy...
March 20, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28017406/bortezomib-with-lenalidomide-and-dexamethasone-versus-lenalidomide-and-dexamethasone-alone-in-patients-with-newly-diagnosed-myeloma-without-intent-for-immediate-autologous-stem-cell-transplant-swog-s0777-a-randomised-open-label-phase-3-trial
#8
Brian G M Durie, Antje Hoering, Muneer H Abidi, S Vincent Rajkumar, Joshua Epstein, Stephen P Kahanic, Mohan Thakuri, Frederic Reu, Christopher M Reynolds, Rachael Sexton, Robert Z Orlowski, Bart Barlogie, Angela Dispenzieri
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant...
February 4, 2017: Lancet
https://www.readbyqxmd.com/read/27459662/estimating-the-economic-impact-of-adding-panobinostat-to-a-u-s-formulary-for-relapsed-and-or-refractory-multiple-myeloma-a-budget-impact-and-cost-benefit-model
#9
Lisa Bloudek, Anuja Roy, Jonathan K Kish, David S Siegel, Sundar Jagannath, Denise Globe, Laurie Orloski, Emil T Kuriakose
BACKGROUND: Multiple myeloma is an incurable B-cell malignancy with a natural history that involves alternating periods of remission and subsequent relapse. For relapsed and/or refractory multiple myeloma (RRMM), the typical patient currently receives more lines of therapy than has been feasible in the past, translating into longer progression-free survival (PFS). Consequently, cost issues have become more prominent because patients may be offered newer and more expensive therapies during a more prolonged overall treatment course...
August 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27273045/the-role-of-internet-resources-in-clinical-oncology-promises-and-challenges
#10
REVIEW
Bradford W Hesse, Alexandra J Greenberg, Lila J Finney Rutten
The Internet is a valuable tool that continues to revolutionize many aspects of our lives; however, the ability to disseminate diverse data across populations and nations presents both opportunities and challenges. Online resources are increasingly used in health care, providing wider access to information for patients, researchers, and clinicians. At the turn of the millennium, the National Cancer Institute (NCI) predicted that Internet-based technologies would create a revolution in communication for oncology professionals and patients with cancer...
December 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27056247/mortality-and-survival-of-lung-cancer-in-denmark-results-from-the-danish-lung-cancer-group-2000-2012
#11
Erik Jakobsen, Torben Riis Rasmussen, Anders Green
Background In the 1990s outcomes in Danish lung cancer patients were poor compared with the other Nordic countries. The five-year survival was only about 5%, only 10% of patients were operated on and less than 60% received active surgical or oncologic treatment. This paper describes trends in mortality and survival of lung cancer in Denmark from 2000 to 2012. Methods The study population comprised 52 435 patients with a diagnosis of cancer of the trachea and the lung, primarily ascertained from the Danish Lung Cancer Register and grouped into three cohorts by year of diagnosis...
June 2016: Acta Oncologica
https://www.readbyqxmd.com/read/26846321/ixazomib-first-global-approval
#12
REVIEW
Matt Shirley
Ixazomib (Ninlaro(®)) is an orally bioavailable, reversible proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. (now Takeda Oncology). Ixazomib acts by binding to and inhibiting the β5 subunit of the 20S proteasome. In November 2015, the US FDA approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is under regulatory review for this indication in the EU. Phase III development of ixazomib is underway worldwide for newly-diagnosed multiple myeloma (in patients who are not eligible for stem cell transplant, or as maintenance therapy) and for relapsed or refractory systemic light chain (AL) amyloidosis...
March 2016: Drugs
https://www.readbyqxmd.com/read/26699315/optimizing-the-mlc-model-parameters-for-imrt-in-the-raystation-treatment-planning-system
#13
Shifeng Chen, Byong Yong Yi, Xiaocheng Yang, Huijun Xu, Karl L Prado, Warren D D'Souza
Unlike other commercial treatment planning systems (TPS) which model the rounded leaf end differently (such as the MLC dosimetric leaf gap (DLG) or rounded leaf-tip radius), the RayStation TPS (RaySearch Laboratories, Stockholm, Sweden) models transmission through the rounded leaf end of the MLC with a step function, in which the radiation transmission through the leaf end is the square root of the average MLC transmission factor. We report on the optimization of MLC model parameters for the RayStation planning system...
September 8, 2015: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/26279055/preliminary-data-on-asp2215-tolerability-and-efficacy-in-acute-myeloid-leukemia-patients
#14
Claire Thom
Claire Thom speaks to Gemma Westcott, Commissioning Editor: Claire Thom joined Astellas in 2013 as the Therapeutic Area Head for Oncology in Global Development. In that role, she also serves as the STAR leader for Oncology for Astellas. Prior to Astellas, she spent 12 years with Takeda. Her last position was Senior Vice President, Portfolio Management, Drug Development Management and Medical Informatics and Strategic Operations within the Medical Division (the Division within Millennium responsible for oncology clinical drug development within Takeda)...
September 2015: Future Oncology
https://www.readbyqxmd.com/read/26219006/is-5-mm-mmlc-suitable-for-vmat-based-lung-sbrt-a-dosimetric-comparison-with-2-5-mm-hdmlc-using-rtog-0813-treatment-planning-criteria-for-both-conventional-and-high-dose-flattening-filter-free-photon-beams
#15
COMPARATIVE STUDY
Shanmuga V Subramanian, Vellaiyan Subramani, Shanmugam Thirumalai Swamy, Arun Gandhi, Srinivas Chilukuri, Murugesan Kathirvel
The aim of this study is to assess the suitability of 5 mm millennium multileaf collimator (MMLC) for volumetric-modulated arc therapy (VMAT)-based lung stereotactic body radiotherapy (SBRT). Thirty lung SBRT patient treatment plans along with their planning target volumes (ranging from 2.01 cc to 150.11 cc) were transferred to an inhomogeneous lung phantom and retrospectively planned using VMAT technique, along with the high definition multileaf collimator (HDMLC) and MMLC systems. The plans were evaluated using Radiation Therapy Oncology Group (RTOG-0813) treatment planning criteria for target coverage, normal tissue sparing, and treatment efficiency for both the MMLC and HDMLC systems using flat and flattening filter-free (FFF) photon beams...
July 8, 2015: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/25456369/safety-and-tolerability-of-ixazomib-an-oral-proteasome-inhibitor-in-combination-with-lenalidomide-and-dexamethasone-in-patients-with-previously-untreated-multiple-myeloma-an-open-label-phase-1-2-study
#16
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Mehdi Hamadani, A Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L Kaufman, Deborah Berg, Eileen Liao, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Ai-Min Hui, Vincent Rajkumar, Paul G Richardson
BACKGROUND: The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. METHODS: We enrolled patients newly diagnosed with multiple myeloma aged 18 years or older with measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and no grade 2 or higher peripheral neuropathy, and treated them with oral ixazomib (days 1, 8, 15) plus lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (days 1, 8, 15, 22) for up to 12 28-day cycles, followed by maintenance therapy with ixazomib alone...
December 2014: Lancet Oncology
https://www.readbyqxmd.com/read/25432410/-r-evolutionary-therapy-the-potential-of-immunotherapy-to-fulfill-the-promise-of-personalized-cancer-treatment
#17
Ravi A Madan, James L Gulley
Since the millennium, personalized medicine has been at the forefront of therapeutic endeavors in medical oncology. The latest technology has given researchers the ability to define cancer at its molecular core. This has led to the development of "targeted therapies," designed to eliminate driver mutations while leaving healthy cells unscathed. Unfortunately, more than 10 years into the targeted molecular therapy era, successes have been infrequent, and toxicity remains largely unchanged compared with relatively indiscriminant, traditional chemotherapy...
January 2015: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/24900352/identification-of-nae-inhibitors-exhibiting-potent-activity-in-leukemia-cells-exploring-the-structural-determinants-of-nae-specificity
#18
Julie L Lukkarila, Sara R da Silva, Mohsin Ali, Vijay M Shahani, G Wei Xu, Judd Berman, Andrew Roughton, Sirano Dhe-Paganon, Aaron D Schimmer, Patrick T Gunning
MLN4924 is a selective inhibitor of the NEDD8-activating enzyme (NAE) and has advanced into clinical trials for the treatment of both solid and hematological malignancies. In contrast, the structurally similar compound 1 (developed by Millennium: The Takeda Oncology Company) is a pan inhibitor of the E1 enzymes NAE, ubiquitin activating enzyme (UAE), and SUMO-activating enzyme (SAE) and is currently viewed as unsuitable for clinical use given its broad spectrum of E1 inhibition. Here, we sought to understand the determinants of NAE selectivity...
August 11, 2011: ACS Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/24899605/head-and-neck-cancer-survivors-patients-and-late-effects-related-to-oncologic-treatment-update-of-literature
#19
REVIEW
R Taibi, A Lleshi, L Barzan, F Fiorica, M Leghissa, E Vaccher, P De Paoli, G Franchin, M Berretta, U Tirelli
Cancer survivorship represents a new challenge in the third Millennium. In Europe the number of cancer survivors was estimated to be 17,8 million in 2008 and this number is growing. Recent improvements in cancer survival are largely due to earlier diagnosis and advancements in treatment. Despite having favorable effects on cancer survival, radiation therapy, surgery treatment and combination chemotherapy regimens can also cause long-term organ damage and functional disabilities. In this paper we review the most important aspects of long-term toxicities in otolaryngology cancer survivors patients...
2014: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/23847379/millennium-losing-its-independence
#20
(no author information available yet)
Takeda Pharmaceutical Company, which bought Millennium Pharmaceuticals five years ago and has 16 oncology programs in active clinical development, announced in May that it will more fully integrate the smaller entity into its operations in an effort to become more efficient.
July 2013: Cancer Discovery
keyword
keyword
15853
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"